Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2015) 39 EP16 | DOI: 10.1530/endoabs.39.EP16

BSPED2015 e-Posters Bone (9 abstracts)

Metformin regulates the differentiation of murine mesenchymal stem cells via AMPK-independent suppression of p70s6-kinase

Suet Ching Chen 1 , Rebecca Brooks 1 , S Faisal Ahmed 1 & Stephen J Yarwood 2


1Developmental Endocrinology Research Group, Royal Hospital for Sick Children, Glasgow, UK; 2College of Medical, Veterinary and Life Sciences, Institute of Molecular, Cell and Systems Biology, University of Glasgow, Glasgow, UK.


Introduction: Metformin is widely used as oral anti-hyperglycaemic agent to treat type 2 diabetes, with increasing reports of an additional, potential bone protective role.

Objective: We investigated the role of AMPK in mediating the effects of metformin on the differentiation of mesenchymal stem cells (MSCs) to either osteoblasts or adipocytes.

Methods: Confluent murine MSCs (C3H10T1/2) were treated with metformin (500 μM), a known AMPK activator (A769662; 100 μM), or the p70S6K inhibitor (rapamycin; 10 μM), in both control and adipogenic-inducing environments (using pioglitazone; 10 μM) for 5 days. Nuclear extracts were separated by SDS–PAGE and immunoblotted with primary antibodies to peroxisome proliferator-activated receptor gamma (PPARγ; marker for adipogenesis), Runt-related transcription factor 2 (Runx2; marker for osteogenesis), phosphorylated-ACC (P-ACC (Ser79); marker for AMPK activity) and phosphorylated-p70s6k (P-p70s6k (Thr389); upstream regulator of mTOR signalling. Immunoblots were scanned using a Licor fluorescent reader. PPARγ and Runx2 activities were determined using Luciferase reporter assays and adipogenesis was quantified histochemically by staining neutral lipids with Oil red O.

Results: MSCs treated with pioglitazone demonstrated marked adipogenic phenotype staining positively with Oil red O. In contrast, treatment with both metformin and A769662 impaired adipogenesis. Pioglitazone induced an (P<0.01) increase in PPARγ expression, whilst metformin and A796662 suppressed PPARγ expression to basal levels, P<0.05 and P<0.01 respectively. Runx2 activity was significantly increased by metformin (P<0.001) and A769662 (P<0.001) but not Runx2 protein levels. As expected, A769662 promotes phosphorylation of ACC, but not so with metformin. Instead, metformin suppressed (P<0.05) the phosphorylation of p70s6k, as did A769662 (P<0.05) and rapamycin (P<0.001). Luciferase reporter assays confirmed the reciprocal action of metformin on adipogenesis and osteogenesis, namely suppression of PPARγ activity (P<0.001) and induction of Runx2 activity (P<0.001).

Conclusions: Metformin suppresses adipogenesis of C3H10T1/2 cells through the reciprocal regulation of PPARγ and Runx2. These results present novel mechanisms of action for metformin on MSC differentiation which is largely AMPK-independent, involving the suppression of p70S6K activity.

Volume 39

43rd Meeting of the British Society for Paediatric Endocrinology and Diabetes

British Society for Paediatric Endocrinology and Diabetes 

Browse other volumes

Article tools

My recent searches

No recent searches.